The recent upheaval at the Centers for Disease Control and Prevention (CDC) signals a pivotal moment not just for public health policy but for investors tracking the intersection of government leadership and healthcare innovation. President … Read more
Susan Monarez’s abrupt exit as CDC Director just weeks after her Senate confirmation is more than a personnel shake-up—it’s a red flag for investors watching the intersection of public health policy, government stability, and market … Read more
Merck’s New RSV Shot: A Game-Changer for Infant Health and What It Means for Investors The recent unanimous recommendation by the revamped Advisory Committee on Immunization Practices (ACIP) to include Merck’s Enflonsia in the government’s … Read more
The recent shakeup at the Advisory Committee on Immunization Practices (ACIP) marks a pivotal moment in U.S. vaccine policy—one that investors and healthcare advisors cannot afford to overlook. Health and Human Services Secretary Robert F. … Read more